Literature DB >> 21985361

Chronic lymphocytic leukaemia cells drive the global CD4+ T cell repertoire towards a regulatory phenotype and leads to the accumulation of CD4+ forkhead box P3+ T cells.

K P Piper1, M Karanth, A McLarnon, E Kalk, N Khan, J Murray, G Pratt, P A H Moss.   

Abstract

Advanced chronic lymphocytic leukaemia (CLL) is associated with profound immunodeficiency, including changes in T regulatory cells (T(regs)). We determined the pattern of expression of forkhead box P3 (FoxP3), CD25, CD27 and CD127 and showed that the frequency of CD4+ FoxP3+ T cells was increased in CLL patients (12% versus 8% in controls). This increase was seen only in advanced disease, with selective expansion of FoxP3-expressing cells in the CD4+ CD25(low) population, whereas the number of CD4+ CD25(high) FoxP3+ cells was unchanged. CD4+ CD25(low) cells showed reduced expression of CD127 and increased CD27, and this regulatory phenotype was also seen on all CD4 T cells subsets in CLL patients, irrespective of CD25 or FoxP3 expression. Incubation of CD4+ T cells with primary CLL tumours led to a sixfold increase in the expression of FoxP3 in CD4+ CD25- T cells. Patients undergoing treatment with fludarabine demonstrated a transient increase in the percentage of CD4+ FoxP3+ T cells, but this reduced to normal levels post-treatment. This work demonstrates that patients with CLL exhibit a systemic T cell dysregulation leading to the accumulation of CD4+ FoxP3+ T cells. This appears to be driven by interaction with malignant cells, and increased understanding of the mechanisms that are involved could provide novel avenues for treatment.
© 2011 The Authors. Clinical and Experimental Immunology © 2011 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21985361      PMCID: PMC3219890          DOI: 10.1111/j.1365-2249.2011.04466.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  51 in total

1.  T-cell responses against chronic lymphocytic leukemia cells: implications for immunotherapy.

Authors:  Angela M Krackhardt; Sabine Harig; Mathias Witzens; Ryan Broderick; Patrick Barrett; John G Gribben
Journal:  Blood       Date:  2002-07-01       Impact factor: 22.113

2.  Control of regulatory T cell development by the transcription factor Foxp3.

Authors:  Shohei Hori; Takashi Nomura; Shimon Sakaguchi
Journal:  Science       Date:  2003-01-09       Impact factor: 47.728

3.  Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.

Authors:  E Y Woo; C S Chu; T J Goletz; K Schlienger; H Yeh; G Coukos; S C Rubin; L R Kaiser; C H June
Journal:  Cancer Res       Date:  2001-06-15       Impact factor: 12.701

4.  CD4+CD25high regulatory cells in human peripheral blood.

Authors:  C Baecher-Allan; J A Brown; G J Freeman; D A Hafler
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

5.  Analysis of the expression of critical activation/interaction markers on peripheral blood T cells in B-cell chronic lymphocytic leukaemia: evidence of immune dysregulation.

Authors:  S Scrivener; E R Kaminski; A Demaine; A G Prentice
Journal:  Br J Haematol       Date:  2001-03       Impact factor: 6.998

6.  Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome.

Authors:  L Fayad; M J Keating; J M Reuben; S O'Brien; B N Lee; S Lerner; R Kurzrock
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

7.  Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.

Authors:  J Shimizu; S Yamazaki; S Sakaguchi
Journal:  J Immunol       Date:  1999-11-15       Impact factor: 5.422

8.  Interleukin 4 content in chronic lymphocytic leukaemia (CLL) B cells and blood CD8+ T cells from B-CLL patients: impact on clonal B-cell apoptosis.

Authors:  N E Kay; L Han; N Bone; G Williams
Journal:  Br J Haematol       Date:  2001-03       Impact factor: 6.998

9.  Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells.

Authors:  W F Ng; P J Duggan; F Ponchel; G Matarese; G Lombardi; A D Edwards; J D Isaacs; R I Lechler
Journal:  Blood       Date:  2001-11-01       Impact factor: 22.113

10.  CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells.

Authors:  Zhi-Zhang Yang; Anne J Novak; Steven C Ziesmer; Thomas E Witzig; Stephen M Ansell
Journal:  Blood       Date:  2007-07-05       Impact factor: 22.113

View more
  13 in total

1.  Regulatory T-cells in chronic lymphocytic leukemia: actor or innocent bystander?

Authors:  Giovanni D'Arena; Vittorio Simeon; Fiorella D'Auria; Teodora Statuto; Paola Di Sanzo; Laura De Martino; Aurelio Marandino; Michele Sangiorgio; Pellegrino Musto; Vincenzo De Feo
Journal:  Am J Blood Res       Date:  2013-01-17

2.  The regulatory capacity of B cells directs the aggressiveness of CLL.

Authors:  Audrey Mohr; Marie Cumin; Cristina Bagacean; Pierre Pochard; Christelle Le Dantec; Sophie Hillion; Yves Renaudineau; Christian Berthou; Adrian Tempescul; Hussam Saad; Jacques-Olivier Pers; Anne Bordron; Christophe Jamin
Journal:  Oncoimmunology       Date:  2018-12-12       Impact factor: 8.110

Review 3.  Regulatory T cells in chronic lymphocytic leukemia: implication for immunotherapeutic interventions.

Authors:  Farhad Jadidi-Niaragh; Ghasem Ghalamfarsa; Mehdi Yousefi; Mina Hajifaraj Tabrizi; Fazel Shokri
Journal:  Tumour Biol       Date:  2013-05-17

Review 4.  Dissecting CLL through high-dimensional single-cell technologies.

Authors:  Satyen H Gohil; Catherine J Wu
Journal:  Blood       Date:  2019-02-06       Impact factor: 25.476

5.  T-cell number and subtype influence the disease course of primary chronic lymphocytic leukaemia xenografts in alymphoid mice.

Authors:  Ceri E Oldreive; Anna Skowronska; Nicholas J Davies; Helen Parry; Angelo Agathanggelou; Sergey Krysov; Graham Packham; Zbigniew Rudzki; Laura Cronin; Katerina Vrzalikova; Paul Murray; Elena Odintsova; Guy Pratt; A Malcolm R Taylor; Paul Moss; Tatjana Stankovic
Journal:  Dis Model Mech       Date:  2015-08-20       Impact factor: 5.758

Review 6.  Regulatory T Cells and Their Prognostic Relevance in Hematologic Malignancies.

Authors:  Giovanni D'Arena; Candida Vitale; Marta Coscia; Agostino Festa; Nicola Matteo Dario Di Minno; Vincenzo De Feo; Michele Caraglia; Gioacchino Calapai; Luca Laurenti; Pellegrino Musto; Giovanni Di Minno; Daniela Fenoglio
Journal:  J Immunol Res       Date:  2017-12-21       Impact factor: 4.818

7.  TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia.

Authors:  Kemal Catakovic; Franz Josef Gassner; Christoph Ratswohl; Nadja Zaborsky; Stefan Rebhandl; Maria Schubert; Markus Steiner; Julia Christine Gutjahr; Lisa Pleyer; Alexander Egle; Tanja Nicole Hartmann; Richard Greil; Roland Geisberger
Journal:  Oncoimmunology       Date:  2017-09-21       Impact factor: 8.110

Review 8.  Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk.

Authors:  Martijn Ha van Attekum; Eric Eldering; Arnon P Kater
Journal:  Haematologica       Date:  2017-08-03       Impact factor: 9.941

Review 9.  Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia.

Authors:  Tom Hofland; Eric Eldering; Arnon P Kater; Sanne H Tonino
Journal:  Int J Mol Sci       Date:  2019-09-03       Impact factor: 5.923

10.  The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide.

Authors:  Hila Shaim; Zeev Estrov; David Harris; Mayra Hernandez Sanabria; Zhiming Liu; Peter Ruvolo; Phillip A Thompson; Alessandra Ferrajoli; May Daher; Jan Burger; Muharrem Muftuoglu; Nobuhiko Imahashi; Li Li; Enli Liu; Abdullah Saleh Alsuliman; Rafet Basar; Lucila Nassif Kerbauy; Catherine Sobieski; Elif Gokdemir; Kayo Kondo; William Wierda; Michael Keating; Elizabeth J Shpall; Katayoun Rezvani
Journal:  Front Immunol       Date:  2018-01-15       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.